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In 1999 a thorough review article in the New England 
Journal of Medicine stated that “Patients with diabetes mellitus 
may represent a special sub-group for whom calcium antagonist 
therapy increases the risks of cardiovascular complications (1).” 
This dictum was met with unanimous approval by 
the medical community since at that time it was clear 
beyond any doubt that diabetes was the sole domain of 
angiotensin converting enzyme (ACE) inhibitors. In 
fact, in what they called a “consensus approach,” a rather 
distinguished group of nephrologists and endocrinologists 
concluded that “in patients with diabetes… the preferred 
initial therapy is an ACE-inhibitor, with the dose titrated 
upward to the moderate or high dose range, as tolerated (2).” 
So powerful was the marketing machine of Big Pharma 
at that time that rather solid evidence of benefits 
of calcium channel blockers (CCB) in diabetes (3), 
showing that CCB based therapy reduced cardiovascular 
morbidity  and mortal i ty  about  twice as  much in 
diabetic than in non-diabetic hypertensive patients 
(Table 1) was completely ignored. The statement of Mancia 
et al. (4) pertaining to the diabetic subpopulation of the 
INSIGHT study “that nifedipine could be considered as first-
line therapy for hypertensive diabetics,” was met with disbelief 
in the US and considered an aberration.
Not that the data for benefits with ACE-inhibitors in 
diabetics were shaky; clearly numerous prospective RCTs 
showed ACE inhibitor therapy to be beneficial in the 
diabetic subpopulation (5,6). Although these benefits were 
initially observed mainly in patients with type 1 diabetes, 
subsequently MICRO-HOPE trial (7) extended these 
benefits to type 2 diabetes subgroup. Angiotensin receptor 
blockers (ARB) soon proved to be equally effective in the 
diabetic population which triggered a lively discussion 
whether or not even normotensive patients with diabetes 
should prophylactically receive renin-angiotensin system 
(RAS) blocker for cardioprotection and nephroprotection. 
Little surprise that with HOPE trial, the ACE-inhibitor 
bandwagon spilled over to non-diabetic hypertensive 
patients as well. Not to initiate antihypertensive therapy with 
either an ACE-inhibitor or an ARB was almost considered 
malpractice in the early 21st century. This, despite the fact 
that whenever other drug classes such as CCBs or even 
thiazide diuretics such as chlorthalidone were pegged 
against RAS-blockers in hypertensive or coronary artery 
disease patients, study after study documented equal or 
even superior outcome of the comparator drug class (8-10). 
However, since many more companies manufactured 
RAS blockers than CCBs there was an overwhelming 
predominance of trials with ACE-inhibitors and ARBs. 
The arrogance of the RAS-blockade evangelists at that 
time is perhaps best documented by the basic hypothesis of 
the VALUE trial (9) which stated “that for the same level of 
blood-pressure (BP) control, valsartan-based treatment would be 
superior to amlodipine-based treatment in reduction of cardiac 
morbidity and mortality” and “valsartan was expected to reduce 
cardiac morbidity beyond its BP-lowering effect.” Amlodipine 
was chosen as comparator because it effectively lowers BP 
but has not been proven to have specific cardioprotective 
properties. 
It was not to be. Quite to the contrary, although there 
was a small BP difference in favor of amlodipine, the 
putative cardioprotective properties of RAS-blockade fell 
miserably short in that both myocardial infarction and 
angina were significantly more common in the valsartan 
than in the amlodipine arm. Some of the relative inefficacy 
of RAS-blockade in ALLHAT and possibly VALUE trials 
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may well has been due to excessive BP variability that 
recently has been documented with this class of drugs (11). 
In contrast, long acting drugs such as chlorthalidone or 
amlodipine provide smoother 24-hour BP control and less 
BP variability.
We recently performed a systematic review and meta-
analysis of randomized trials in over 25,000 patients 
asking the question whether diabetes mellitus remained 
a compelling indication for use of renin angiotensin 
system blockers (12). It turned out that RAS blockers are 
not superior to other antihypertensive drug classes such 
as thiazides, CCB, and β blockers at reducing the risk of 
hard cardiovascular and renal endpoints. There was also 
no difference in the hard renal outcome of end stage renal 
disease. Our findings support the recommendations of the 
guidelines of the European Society of Cardiology/European 
Society of Hypertension and eighth Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure that there is convincing 
evidence to use any antihypertensive agents including RAS-
blockers in patients with diabetes (13,14).
The recent paper of Barzilay et al. (15) further explores 
the question of whether RAS blockade deserves to have 
preferred status over other anti-hypertensive medications 
for the treatment of people with diabetes. After thoroughly 
going through studies in aggregate, the authors note that 
contrary to many current guidelines and “accepted medical 
dogma” patients with diabetes mellitus and hypertension, 
renal disease, or cardiovascular disease should be treated 
with an ACE-inhibitor or an ARB is not supported by 
evidence. To the contrary, they conclude similar to the 
panel members appointed to the Eighth Joint National 
Commission on the Treatment of Hypertension that of 
antihypertensive medications that lower BP effectively 
should be the preferred approach to treatment and do not 
advocate for preferential use of any class of antihypertensive 
medication.
We thoroughly agree.
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